Department of Plastic Surgery, Cleveland Clinic, Cleveland, OH.
Aesthet Surg J. 2021 Mar 12;41(4):391-397. doi: 10.1093/asj/sjaa198.
Rebound bleeding during facelift surgery is a major cause of facelift hematomas. Subcutaneous infiltration of tranexamic acid (TXA) combined with lidocaine and epinephrine was recently retrospectively shown to decrease rebound bleeding. No study has prospectively examined the effect of subcutaneous TXA on intraoperative and postoperative bleeding during facelift surgery.
The aim of this study was to prospectively demonstrate that TXA combined with local anesthesia safely reduces the effects of rebound bleeding, reduces operative time, and decreases postoperative drainage.
This was a prospective, single-surgeon, case-control study performed between July 2019 and March 2020. Thirty-nine patients (35 female and 4 male; mean age, 64.9 years; age range, 49-80 years) underwent facelift surgery alone or in combination with facial rejuvenation procedures. All patients were injected subcutaneously with 1 or 2 mg/mL TXA + 0.5% lidocaine/1:200,000 epinephrine. Patient demographics, TXA dose, time to hemostasis, drain output, and minor and major complications were recorded.
The mean time to hemostasis was 6.4 minutes for the left and right sides each. Average postoperative day (POD) 0 drain outputs were 13.9 mL (left) and 10.1 mL (right). Average POD 1 drain outputs were 15.1 mL (left) and 15.6 mL (right). Drains were removed from all patients on POD 1 or 2. There were 2 minor complications (flap necrosis plus infection, marginal mandibular neuropraxia) and no major complications.
TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic techniques. Our future goal is to determine if epinephrine can be completely removed from the local anesthetic and replaced with TXA for facelift surgery.
面部提升术中的回弹性出血是面部提升血肿的主要原因。最近回顾性研究表明,将氨甲环酸(TXA)与利多卡因和肾上腺素皮下浸润可减少回弹性出血。没有研究前瞻性地检查 TXA 对面部提升术中及术后出血的影响。
本研究旨在前瞻性证明 TXA 联合局部麻醉可安全减少回弹性出血、缩短手术时间并减少术后引流。
这是一项前瞻性、单外科医生、病例对照研究,于 2019 年 7 月至 2020 年 3 月进行。39 例患者(35 名女性和 4 名男性;平均年龄 64.9 岁;年龄范围 49-80 岁)单独接受面部提升手术或与面部年轻化手术联合进行。所有患者均接受 1 或 2mg/mL TXA+0.5%利多卡因/1:200,000 肾上腺素皮下注射。记录患者人口统计学资料、TXA 剂量、止血时间、引流量以及轻微和严重并发症。
左侧和右侧止血的平均时间分别为 6.4 分钟。术后第 0 天(POD)0 引流量分别为 13.9 毫升(左侧)和 10.1 毫升(右侧)。术后第 1 天(POD)1 引流量分别为 15.1 毫升(左侧)和 15.6 毫升(右侧)。所有患者均在 POD1 或 POD2 时去除引流管。有 2 例轻微并发症(皮瓣坏死伴感染、下颌缘神经麻痹),无严重并发症。
与传统局部麻醉技术相比,TXA 可安全有效地减少出血、手术室时间和引流量。我们的未来目标是确定肾上腺素是否可从局部麻醉中完全去除并用 TXA 代替,用于面部提升术。